Meeder Asset Management’s MyoKardia, Inc. Common Stock MYOK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-2,009
| Closed | -$273K | – | 2415 |
|
|
2020
Q3 | $273K | Sell |
2,009
-306
| -13% | -$32.5K | 0.02% | 527 |
|
|
2020
Q2 | $224K | Buy |
+2,315
| New | +$193K | 0.01% | 573 |
|
|
2019
Q3 | – | Sell |
-575
| Closed | -$29K | – | 2329 |
|
|
2019
Q2 | $29K | Buy |
575
+35
| +6% | +$1.7K | ﹤0.01% | 1123 |
|
|
2019
Q1 | $28K | Buy |
540
+408
| +309% | +$18.8K | ﹤0.01% | 996 |
|
|
2018
Q4 | $6K | Hold |
132
| – | – | ﹤0.01% | 1386 |
|
|
2018
Q3 | $9K | Sell |
132
-48
| -27% | -$2.82K | ﹤0.01% | 1199 |
|
|
2018
Q2 | $8.94K | Sell |
180
-193
| -52% | -$9.34K | ﹤0.01% | 1144 |
|
|
2018
Q1 | $18K | Buy |
373
+64
| +21% | +$3.33K | ﹤0.01% | 919 |
|
|
2017
Q4 | $14K | Buy |
309
+84
| +37% | +$3.24K | ﹤0.01% | 1052 |
|
|
2017
Q3 | $10K | Sell |
225
-41
| -15% | -$1.31K | ﹤0.01% | 1087 |
|
|
2017
Q2 | $3K | Sell |
266
-88
| -25% | -$1.16K | ﹤0.01% | 1359 |
|
|
2017
Q1 | $5K | Buy |
+354
| New | +$4.54K | ﹤0.01% | 1119 |
|
Meeder Asset Management's MYOK Position: Q4 2020 in Review
Meeder Asset Management sold out of MyoKardia, Inc. Common Stock (MYOK) in Q4 2020, closing a stake of 2,009 shares — an estimated $273K sold.
Meeder Asset Management first reported a position in MYOK in Q1 2017 and held it in 12 quarters. The position peaked at $273K in Q3 2020. 0 funds tracked by Wall St. Rank hold MYOK as of Q4 2020.
- Meeder Asset Management reported no remaining MyoKardia, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
- Meeder Asset Management sold 2,009 MyoKardia, Inc. Common Stock shares in Q4 2020, an estimated $273K.
- Meeder Asset Management first reported a position in MyoKardia, Inc. Common Stock in Q1 2017 and held it in 12 quarters.
- Meeder Asset Management's MyoKardia, Inc. Common Stock position peaked at $273K in Q3 2020.
- 0 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q4 2020.
Based on Meeder Asset Management's 13F filing for Q4 2020, filed 9 Feb 2021.